Jun 2 2010
AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans. Using the HuALN technology AFFiRiS anticipates accelerating the progression of its human vaccine candidates into clinical trials.
"We have been looking for a system like the Human Artificial Lymph Node for quite a long time and are excited by the possibilities the system offers to test our peptide vaccine candidates which are delivered by our proprietary AFFITOME® technology", commented Walter Schmidt, CEO of AFFiRiS.
"AFFiRiS with its cutting-edge technology in the vaccine field is an ideal partner to further underline the strengths of ProBioGen's HuALN technology. We are very much looking forward to this co-operation" said Michael Schlenk, CEO of ProBioGen.
About AFFiRiS AG
www.affiris.com
Can exercise undo sitting's health risks? New study suggests vigorous activity helps